• Je něco špatně v tomto záznamu ?

Fanconi anemia with biallelic FANCD1/BRCA2 mutations - Case report of a family with three affected children

K. Svojgr, D. Sumerauer, A. Puchmajerova, A. Vicha, O. Hrusak, K. Michalova, J. Malis, P. Smisek, M. Kyncl, D. Novotna, E. Machackova, J. Jencik, K. Pycha, M. Vaculik, R. Kodet, J. Stary,

. 2016 ; 59 (3) : 152-7. [pub] 20151202

Jazyk angličtina Země Nizozemsko

Typ dokumentu kazuistiky, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc17000787

Fanconi anemia, complementation group D1 with bi-allelic FANCD1 (BRCA2) mutations, is a very rare genetic disorder characterized by early onset of childhood malignancies, including acute leukemia, brain cancer and nephroblastoma. Here, we present a case report of a family with 3 affected children in terms of treatment outcome, toxicity and characterization of the malignancies using comprehensive cytogenetic analysis. The first child was diagnosed with T-cell acute lymphoblastic leukemia when he was 11 months old. During chemotherapy, he suffered from repeated pancytopenia, sepsis and severe vincristine polyneuropathy, and 18 months after primary diagnosis, he succumbed to secondary acute monocytic leukemia. The second child was diagnosed with stage 2 triphasic nephroblastoma (Wilms tumor), when he was 3 years and 11 months old. During chemotherapy, he suffered from vincristine polyneuropathy. Currently, he is in complete remission, 29 months following the initial diagnosis. The third child was diagnosed with medulloblastoma with classical histology, when she was 4 years and 5 months old. After the first cycle of chemotherapy, she suffered from prolonged pancytopenia, sepsis and severe skin and mucosal toxicity. Six weeks after primary diagnosis, a first relapse in the posterior fossa was diagnosed, and at 7 and half months after primary diagnosis, a second relapse was diagnosed that led to the patient's death. Our case report underscores tumor heterogeneity, treatment toxicity and poor outcome in Fanconi anemia patients of complementation group D1.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17000787
003      
CZ-PrNML
005      
20170116095423.0
007      
ta
008      
170103s2016 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejmg.2015.11.013 $2 doi
024    7_
$a 10.1016/j.ejmg.2015.11.013 $2 doi
035    __
$a (PubMed)26657402
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Svojgr, Karel $u Department of Pediatric Hematology and Oncology, Charles University in Prague, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic. Electronic address: karel.svojgr@fnmotol.cz.
245    10
$a Fanconi anemia with biallelic FANCD1/BRCA2 mutations - Case report of a family with three affected children / $c K. Svojgr, D. Sumerauer, A. Puchmajerova, A. Vicha, O. Hrusak, K. Michalova, J. Malis, P. Smisek, M. Kyncl, D. Novotna, E. Machackova, J. Jencik, K. Pycha, M. Vaculik, R. Kodet, J. Stary,
520    9_
$a Fanconi anemia, complementation group D1 with bi-allelic FANCD1 (BRCA2) mutations, is a very rare genetic disorder characterized by early onset of childhood malignancies, including acute leukemia, brain cancer and nephroblastoma. Here, we present a case report of a family with 3 affected children in terms of treatment outcome, toxicity and characterization of the malignancies using comprehensive cytogenetic analysis. The first child was diagnosed with T-cell acute lymphoblastic leukemia when he was 11 months old. During chemotherapy, he suffered from repeated pancytopenia, sepsis and severe vincristine polyneuropathy, and 18 months after primary diagnosis, he succumbed to secondary acute monocytic leukemia. The second child was diagnosed with stage 2 triphasic nephroblastoma (Wilms tumor), when he was 3 years and 11 months old. During chemotherapy, he suffered from vincristine polyneuropathy. Currently, he is in complete remission, 29 months following the initial diagnosis. The third child was diagnosed with medulloblastoma with classical histology, when she was 4 years and 5 months old. After the first cycle of chemotherapy, she suffered from prolonged pancytopenia, sepsis and severe skin and mucosal toxicity. Six weeks after primary diagnosis, a first relapse in the posterior fossa was diagnosed, and at 7 and half months after primary diagnosis, a second relapse was diagnosed that led to the patient's death. Our case report underscores tumor heterogeneity, treatment toxicity and poor outcome in Fanconi anemia patients of complementation group D1.
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a protein BRCA2 $x genetika $7 D024682
650    _2
$a předškolní dítě $7 D002675
650    _2
$a rodina $7 D005190
650    _2
$a Fanconiho anemie $x diagnóza $x farmakoterapie $x genetika $7 D005199
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a imunofenotypizace $7 D016130
650    _2
$a hybridizace in situ fluorescenční $7 D017404
650    _2
$a ztráta heterozygozity $7 D019656
650    _2
$a magnetická rezonanční tomografie $7 D008279
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a fenotyp $7 D010641
650    _2
$a jednonukleotidový polymorfismus $7 D020641
655    _2
$a kazuistiky $7 D002363
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Sumerauer, David $u Department of Pediatric Hematology and Oncology, Charles University in Prague, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Puchmajerova, Alena $u Department of Biology and Medical Genetics, Charles University in Prague, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Vicha, Ales $u Department of Pediatric Hematology and Oncology, Charles University in Prague, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Hrusak, Ondrej $u Department of Pediatric Hematology and Oncology, Charles University in Prague, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Michalova, Kyra $u Center of Oncocytogenetics, General Teaching Hospital, Prague, Czech Republic.
700    1_
$a Malis, Josef $u Department of Pediatric Hematology and Oncology, Charles University in Prague, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Smisek, Petr $u Department of Pediatric Hematology and Oncology, Charles University in Prague, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Kyncl, Martin $u Department of Radiology, Charles University in Prague, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Novotna, Drahuse $u Department of Biology and Medical Genetics, Charles University in Prague, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Machackova, Eva $u Department of Epidemiology and Cancer Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Jencik, Jan $u Czech Gene Bank, Prague, Czech Republic.
700    1_
$a Pycha, Karel $u Department of Pediatric Surgery, Charles University in Prague, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Vaculik, Miroslav $u Department of Neurosurgery, Charles University in Prague, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Kodet, Roman $u Department of Pathology and Molecular Medicine, Charles University in Prague, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Stary, Jan $u Department of Pediatric Hematology and Oncology, Charles University in Prague, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
773    0_
$w MED00166495 $t European journal of medical genetics $x 1878-0849 $g Roč. 59, č. 3 (2016), s. 152-7
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26657402 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20170116095528 $b ABA008
999    __
$a ok $b bmc $g 1179927 $s 961354
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 59 $c 3 $d 152-7 $e 20151202 $i 1878-0849 $m European journal of medical genetics $n Eur. J. med. genet. $x MED00166495
LZP    __
$a Pubmed-20170103

Najít záznam

Citační ukazatele

Možnosti archivace